Netherlands Most cancers Institute. Photograph/NKI
Proscia, a supplier of digital and computational pathology options, has introduced that the Netherlands Cancer Institute (NKI), one of many prime 10 complete most cancers facilities in Europe, will deploy its Concentriq Dx platform.
NKI is transitioning to Concentriq Dx to develop its digital pathology follow, so its pathologists can ship customized diagnoses that higher inform remedy selections. In doing so, the most cancers heart will generate extra pathology knowledge that may result in medical breakthroughs.
Digital pathology, which shifts the 150-year-old normal of care from microscope to a complete slide picture, is more and more powering routine analysis as expectations for precision medication intensify the affect of the pathologist scarcity and rising most cancers burden. An early adopter, NKI acknowledged that scaling its digital operations to additional ship on its dedication to glorious affected person care would require transferring away from its legacy software program system. It chosen Concentriq Dx to function the trendy platform on the heart of its rising oncology follow.
Concentriq Dx is a singular, safe digital pathology platform that drives major diagnostic and different routine workflows throughout the linked laboratory. NKI will draw on the platform’s world-class interoperability to unify photographs from disparate scanners, bringing extra pathology knowledge into its follow. With reside and asynchronous collaboration and distant picture viewing, Concentriq Dx helps pathologists to broaden entry to specialists in an effort to offer increased high quality diagnoses. The platform additionally affords interoperability with third-party picture evaluation purposes, permitting NKI to determine clinically impactful patterns, and is designed for realizing the promise of pathology’s computational future.
“Concentriq Dx will empower us to chart our path in the direction of full digitization,” mentioned José van den Berg, Head of the Division of Pathology at NKI. “The fashionable, enterprise-grade platform will allow us to more and more mix experience and perception to drive precision analysis. Our multidisciplinary groups work to offer customized remedy for all sufferers, and our pathology knowledge performs an integral position in attaining this intention.”
Pathology knowledge elements closely into biomedical analysis that results in new therapies and different breakthroughs that advance precision medication and enhance affected person care.
